Zerit licence restricted

HIV virus
HIV virus

Zerit (stavudine) is now indicated for use in patients with HIV infection only when other antiretrovirals cannot be used and then only for the shortest time possible with a switch to alternative therapy as soon as appropriate.

The SPC for the nucleoside reverse transcriptase inhibitor states that given the severe side effects associated with stavudine therapy, including lactic acidosis, lipoatrophy and polyneuropathy, a benefit-risk assessment should be conducted for each patient and use of an alternative antiretroviral carefully considered.

View Zerit drug record

Further information: Bristol-Myers Squibb

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic guidance for diabetic foot infection

New antibiotic guidance for diabetic foot infection

NICE has updated its guidance on the prevention and...

Drug shortages - live tracker

Drug shortages - live tracker

Added: co-fluampicil.
Use our constantly updated...

Further drug shortages prompt advice to consider unlicensed alternatives

Further drug shortages prompt advice to consider unlicensed alternatives

Prescribers are being advised to prioritise supplies...

Vaping still safer than smoking, say health bosses after report of severe lung injury